Skip to search formSkip to main contentSkip to account menu

PLX3397

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Pexidartinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced…
11509Background: Most metastatic GISTs have primary (10) mut in KIT exons (ex) 9 or 11, which confer sensitivity to imatinib and… 
2016
2016
Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion.
Glioblastoma multiforme (grade IV glioma) is a very aggressive human cancer with a median survival of 1 year post diagnosis… 
2016
2016
ACTR-20. INITIAL RESULTS OF PLX108-08: AN OPEN LABEL PHASE 1B/2 STUDY OF ORALLY ADMINISTERED PEXIDARTINIB (PLX3397) IN COMBINATION WITH RADIATION THERAPY AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY…
BACKGROUND: Pexidartinib (PEX) is a small molecule inhibitor of KIT and the CSF1 receptor expressed on microglia, blood vessels… 
2015
2015
Structural Approaches to Cancer Drug Development.
The design of a new CSF1R inhibitor reveals how medicinal chemists can now examine drug interactions with three-dimensional forms… 
2013
2013
Preclinical and Clinical Resistance Mechanisms To The Investigational Selective FLT3 Inhibitor PLX3397 In FLT3-ITD+ Acute Myeloid Leukemia (AML)
Background Activating mutations [primarily internal tandem duplication (ITD) events] in FLT3 are detected in 30% of acute myeloid… 
2012
2012
c-Fms Signaling Mediates Neurofibromatosis Type-1 Osteoclast Gain-In-Functions
Skeletal abnormalities including osteoporosis and osteopenia occur frequently in both pediatric and adult neurofibromatosis type… 
2012
2012
Microglial stimulation of glioblastoma invasion involves EGFR and CSF-1 R signaling
Glioblastoma multiforme is a deadly cancer whose current treatment options are limited. The ability of glioblastoma tumor cells… 
2011
2011
PLX3397 Is An Investigational Selective FLT3 Inhibitor That Retains Activity Against the Clinically-Relevant FLT3-ITD/F691L “Gatekeeper” Mutation in Vitro
Abstract 764 Background: Activating mutations in FLT3 are detected in approximately 30% of adult acute myeloid leukemia (AML… 
2011
2011
Abstract 552: Targeting brain tumors with PLX3397, an inhibitor of the CSF-1 receptor kinase
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Cancer growth in the brain incites a neuroinflammatory… 
2010
2010
Abstract 3850: Efficacy of the selective CSF-1R kinase inhibitor PLX3397 in mouse models of tumor growth and bone metastasis
Macrophages of the tumor microenvironment can facilitate cancer progression and are a possible target for therapy. We have… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)